PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27834881-3	2016	SDS inhibited LPS-triggered phosphorylation of LPS-activated kinase 1 (TAK1), p38, c-Jun terminal kinase (JNK), and extracellular signal-regulated kinase (ERK).	rhodioloside	0-3	mitogen-activated protein kinase 14	Mus musculus	78-81	
31878993-6	2019	In addition, after the stimulation of DCs by SAL, the expression of p38 MAPK and phosphorylated c-jun N-terminal kinase (p-JNK) was detected by flow cytometry.	rhodioloside	45-48	mitogen-activated protein kinase 14	Mus musculus	68-71	
24864151-8	2014	Moreover, salidroside suppressed LPS-induced activation of nuclear factor kappa B (NF- kappa B) by blocking degradation of I kappa B alpha and phosphorylation of MAPK (p38, JNK, ERK1/2), which resulted in inhibition of chemokine expression.	rhodioloside	10-21	mitogen-activated protein kinase 14	Mus musculus	168-171	
22915087-6	2013	Further studies revealed that salidroside down-regulated phosphorylation of LPS-induced nuclear transcription factor-kappaB (NF-kappaB) p65 and inhibitor of NF-kappaB alpha (IkappaBalpha) in the NF-kappaB signal pathway, and suppressed phosphorylation of p38, extracellular signal-regulated kinase (ERK) and c-jun NH(2)-terminal kinase (JNK) in MAPKs signal pathways.	rhodioloside	30-41	mitogen-activated protein kinase 14	Mus musculus	255-258	
32910486-5	2020	SAL led to the up-regulation of the serum glucagon-like peptide 1 (GLP-1) level by facilitating the SCFAs production, the promotion of GLP-1 synthesis by improving p38 MAPK phosphorylation and regulating insulin resistance.	rhodioloside	0-3	mitogen-activated protein kinase 14	Mus musculus	164-172	
32910486-10	2020	PRACTICAL APPLICATIONS: Our data showed that SAL could increase the GLP-1 level by stimulating the SCFAs production and p38 phosphorylation and facilitate the IR and GLP-1 synthesis by alleviating ROS-mediated activation of MAPKs signaling pathway and mitigating apoptosis.	rhodioloside	45-48	mitogen-activated protein kinase 14	Mus musculus	120-123	
31682803-9	2020	In addition, our data also showed a marked downregulation the fluorescence expressions of p38 MAPK phosphorylation and upregulation the protein expressions of ZO-1, Occludin, Claudin-11 and N-cadherin after SAL administration (100 mg/kg) compared with the type-1 diabetic group.	rhodioloside	207-210	mitogen-activated protein kinase 14	Mus musculus	90-93	
31849652-8	2019	Western blot analysis revealed that Sal inhibited p65 and p38 activation together with peroxisome proliferator-activated receptor (PPARgamma) up-regulation.	rhodioloside	36-39	mitogen-activated protein kinase 14	Mus musculus	58-61	
28831032-13	2017	ILK/Akt, JNK, ERK1/2, p38 MAPK, and Nrf-2 are involved in salidroside-decreased podocyte apoptosis in HG condition.	rhodioloside	58-69	mitogen-activated protein kinase 14	Mus musculus	22-30	
30586667-14	2019	Furthermore, SAL inactivated NF-kappaB and p38MAPK signaling pathways by regulating miR-145.	rhodioloside	13-16	mitogen-activated protein kinase 14	Mus musculus	43-50	
29926065-0	2018	[Salidroside inhibits inflammatory factor release in BV-2 cells through p38 and JNK pathways].	rhodioloside	1-12	mitogen-activated protein kinase 14	Mus musculus	72-75	
29926065-9	2018	The result showed that salidroside pretreatment decreased the expression of IL-6 and TNF-alpha as well as phosphorylation of p38 and JNK induced by LPS in BV-2 cells.	rhodioloside	23-34	mitogen-activated protein kinase 14	Mus musculus	125-128